Sign in

    Kristin C. Peck

    Chief Executive Officer and Director at Zoetis Inc
    Board
    Since January 2020
    Age
    53 years
    Education
    Earned a bachelor’s degree from Georgetown University and an MBA from Columbia Business School.
    Tenure
    Joined ZTS in October 2012 as Executive Vice President and Group President, then served as President of U.S. Operations before becoming CEO in January 2020 and a Director in October 2019.

    Also at Zoetis Inc

    JB
    Jamie Brannan
    Executive Vice President and Chief Commercial Officer
    JS
    Jared Shriver
    President of U.S. Operations
    KS
    Keith Sarbaugh
    Executive Vice President and Chief Digital & Technology Officer

    About

    Kristin C. Peck is 53 years old and has built a distinguished career in the pharmaceutical and animal health industries. She started her professional journey with roles in private equity, real estate finance, and consulting before moving on to senior leadership positions at Pfizer Inc..

    At ZTS, she joined in October 2012 as Executive Vice President and Group President, playing a key role in the company’s early growth and its IPO in 2013. She later advanced to lead U.S. operations and strategic growth initiatives, demonstrating her expertise in global manufacturing, supply chain, and market research.

    In January 2020, she assumed her current role as Chief Executive Officer while also taking on the responsibilities of a Director in October 2019, solidifying her impact on the company's strategic direction and innovation. Her extensive experience is further enriched by her previous leadership roles and board memberships, underscoring a commitment to driving value and operational excellence across the industry.

    $ZTS Performance Under Kristin C. Peck

    Past Roles

    OrganizationRoleDate RangeDetails
    Zoetis (ZTS) Executive Vice President and Group President, U.S. Operations, Business Development and Strategy March 2018 - December 2019 Oversaw U.S. operations, business development, and strategy
    Zoetis (ZTS) Executive Vice President and President, U.S. Operations May 2015 - February 2018 Led U.S. operations
    Zoetis (ZTS) Executive Vice President and Group President October 2012 - April 2015 Oversaw business development, global manufacturing & supply, marketing, and sales; played a key role in the IPO in 2013
    Pfizer Inc. Executive Vice President, Worldwide Business Development and Innovation February 2004 - October 2012 Member of the Executive Leadership Team; gained experience in human capital management
    The Boston Consulting Group (BCG) Various Roles 1999 - 2004 Held multiple roles at BCG
    The Prudential Realty Group, The O’Connor Group, and J.P. Morgan Private Equity and Real Estate Finance Roles N/A Specific dates not provided

    External Roles

    OrganizationRoleDate RangeDetails
    BlackRock Board of Directors Since September 2021 N/A
    Mayo Clinic Board of Trustees N/AN/A
    Catalyst Board of Directors N/AGlobal non-profit organization focused on accelerating women into leadership roles

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary $1,200,000AnnualFixed annual base salary.
    Company Contributions to Defined Contribution Plan (ZSP) $29,700AnnualPart of All Other Compensation for 2023.
    Company Contributions under Zoetis Supplemental Savings Plan (ZSSP) $196,560AnnualPart of All Other Compensation for 2023.
    Other Compensation $5,766AnnualIncludes imputed income for excess group term life insurance and $275 of matching contributions from the Zoetis Foundation.

    Performance Compensation

    Data from  FY 2023

    Annual Incentive Plan (AIP)

    • Performance Metrics: Holistic assessment including Zoetis’ financial performance (revenue, adjusted diluted EPS, free cash flow), performance of the region/business unit (annual revenue and income before adjustments), and individual performance aligned with Zoetis’ Core Beliefs.
    • Payout Structure:
      • Threshold: $0
      • Target: $1,800,000
      • Maximum (Cap): $3,600,000
      • Actual Payout: 117% of target resulting in $2,106,000
    • Payment Schedule: Award determined based on fiscal year 2023 performance; paid the following February (2024).
    • Additional Details: The target annual incentive opportunity was set at 150% of the base salary.

    Performance Award Units (PAUs)

    • Performance Metric: Relative Total Shareholder Return (Relative TSR) compared to companies in the S&P 500 Group over a three-year period.
    • Evaluation Period: January 1, 2023 to December 31, 2025.
    • Payout Range: 0% to 200% of the target number of shares.
    • Target Units: 24,555 units
    • Maximum Units: 49,110 units
    • Grant Details:
      • Grant Date: February 8, 2023
      • Grant Date Fair Value: $5,849,983
      • Grant Date Stock Price: $162.07 per share
    • Vesting Schedule: 3-year cliff vesting; 100% vests on February 8, 2026.
    • Conditions: Continued employment through the vesting date and achievement of the Relative TSR performance goal.

    This performance compensation package for 2023 combines a cash incentive based on the company's financial and operational performance (AIP) with a long-term, share-based award (PAUs) tied to the Relative TSR metric.